Fluorescence in situ hybridization identifies high risk Barrett's patients likely to develop esophageal adenocarcinoma.

about

A Multicenter Study of a Fluorescence In Situ Hybridization Probe Set for Diagnosing High-Grade Dysplasia and Adenocarcinoma in Barrett's Esophagus.MicroRNA Expression Signatures During Malignant Progression From Barrett's Esophagus.

P2860

Q38925807-79438B16-F90E-48B3-A0CA-F43F96D6E409 Q48065525-EC1AF3C9-B2E3-4A2A-817D-554C7499F596

P2860

Fluorescence in situ hybridization identifies high risk Barrett's patients likely to develop esophageal adenocarcinoma.

Item

http://www.wikidata.org/entity/Q41465141

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Fluorescence in situ hybridiza ...... lop esophageal adenocarcinoma.

@en

type

Item

label

Fluorescence in situ hybridiza ...... lop esophageal adenocarcinoma.

@en

prefLabel

Fluorescence in situ hybridiza ...... lop esophageal adenocarcinoma.

@en

P1476

Fluorescence in situ hybridiza ...... lop esophageal adenocarcinoma.

@en

P2093

B R Kipp

http://www.w3.org/2001/XMLSchema#string

D M Minot

http://www.w3.org/2001/XMLSchema#string

E G Barr Fritcher

http://www.w3.org/2001/XMLSchema#string

J S Voss

http://www.w3.org/2001/XMLSchema#string

K C Halling

http://www.w3.org/2001/XMLSchema#string

K K Wang

http://www.w3.org/2001/XMLSchema#string

L S Lutzke

http://www.w3.org/2001/XMLSchema#string

M B Campion

http://www.w3.org/2001/XMLSchema#string

M R Timmer

http://www.w3.org/2001/XMLSchema#string

P G Iyer

http://www.w3.org/2001/XMLSchema#string

P2860

NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma

Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis

Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus.

TP53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort

The development of a fluorescence in situ hybridization assay for the detection of dysplasia and adenocarcinoma in Barrett's esophagus.

Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study

Population-based study reveals new risk-stratification biomarker panel for Barrett's esophagus.

Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial.

A comparison of conventional cytology, DNA ploidy analysis, and fluorescence in situ hybridization for the detection of dysplasia and adenocarcinoma in patients with Barrett's esophagus.

Defining Cancer Risk in Barrett's Esophagus: A Pathologist's Perspective.

P304

513-519

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/DOTE.12372

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Thomas C. Smyrk

P577

2015-06-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26043762

http://www.w3.org/2001/XMLSchema#string

P932

5563668

http://www.w3.org/2001/XMLSchema#string

Fluorescence in situ hybridization identifies high risk Barrett's patients likely to develop esophageal adenocarcinoma.

about

P2860

P2860

Fluorescence in situ hybridization identifies high risk Barrett's patients likely to develop esophageal adenocarcinoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932